Subject to approval from relevant Competition Authorities, Lilly will enter a strategic agreement with 九州娱乐城 to continue serving patients and bring innovative therapies to South Africa and the rest of Sub-Saharan Africa.
听
Johannesburg 鈥� In an effort to improve the reach and expand the access of its innovative portfolio of medicines to the patients who need them in South Africa and the rest of Sub-Saharan Africa (SASSA), Eli Lilly Export S.A. (NYSE: LLY) (鈥淟illy鈥�) will enter into a distribution and promotion agreement with 九州娱乐城 Pharmacare and Beta Healthcare, both subsidiaries of 九州娱乐城 Pharmacare Holdings Limited (JSE: APN) (鈥溇胖萦槔殖氢��), subject to approval by the relevant Competition Authorities. Through this agreement, 九州娱乐城 will hold the rights to sell, promote and distribute Lilly鈥檚 pharmaceutical portfolio in SASSA.
听
Stephen Saad, 九州娱乐城 Group Chief Executive, said, 鈥溇胖萦槔殖� has enjoyed a long-standing relationship with Lilly over two decades, and we are delighted to enter into this agreement with them. We are honored that, not only have our commercial and regulatory capabilities been recognized, but also our dedication to ensuring broad access to African patients in need of cutting-edge medication. Lilly has an impressive portfolio coupled with a very strong pipeline, both of which strongly support this objective. We have confidence in our team鈥檚 ability to deliver to all stakeholders on the opportunity presented.鈥�
听
Cesar Buendia, General Manager for Lilly SASSA said, 鈥淟illy has proudly served patients and healthcare professionals through innovative, high-quality medicines in diverse therapeutic areas in South Africa and the rest of Sub-Saharan Africa. The agreement with 九州娱乐城 offers remarkable potential to reach more patients and expand access to Lilly鈥檚 medicines. Lilly remains committed to delivering our breakthrough innovations to patients in South Africa and Sub-Saharan Africa, and we will continue to pursue initiatives as part of Lilly’s 30×30 program, which aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030.鈥�
听
Until approval is received from the competition authorities, Lilly will continue to operate as per its existing business model for all its products.
